Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular Phase I, Open-label Study to Assess the Safety, Pharmacokinetics, and Drug Interaction Potential and Relative Bioavailability of Saruparib in Patients With Advanced Solid Malignancies

NCT06899061 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06899061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06899061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular Phase I, Open-label Study to Assess the Safety, Pharmacokinetics, and Drug Interaction Potential and Relative Bioavailability of Saruparib in Patients With Advanced Solid Malignancies
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 25, 2025
Completion date
May 19, 2028
Enrollment
41 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid malignancies